Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific's regulatory disclosures and financial reporting.
Core Scientific, Inc. filed an amended quarterly report to restate prior financial statements after identifying material errors in accounting for property, plant and equipment. Assets committed to demolition during the shift from bitcoin mining to high-performance computing colocation were left capitalized instead of being impaired.
The correction reduced property, plant and equipment, net, by about $127.3 million as of March 31 2025 and increased accumulated deficit by the same amount, and raised selling, general and administrative expense for the quarter by about $4.4 million. Revenue for the quarter remained $79.5 million, but gross profit dropped to $8.2 million.
Despite this, Core Scientific reported net income of $576.3 million for the quarter, largely driven by a $621.5 million non‑cash gain from changes in the fair value of warrants and contingent value rights. Operating cash flow was a $45.0 million outflow, and cash, cash equivalents and restricted cash ended at $698.7 million.
The company concluded the errors were material and that earlier financial statements for several 2024 and 2025 periods should no longer be relied upon. Management identified a material weakness in internal control over financial reporting and deemed controls ineffective for the 2024 and 2025 year‑ends and interim 2025 non‑reliance periods, and outlines remediation plans in its controls discussion.
Core Scientific, Inc. filed an amended quarterly report to restate prior financial statements after identifying material errors in accounting for property, plant and equipment. Assets committed to demolition during the shift from bitcoin mining to high-performance computing colocation were left capitalized instead of being impaired.
The correction reduced property, plant and equipment, net, by about $127.3 million as of March 31 2025 and increased accumulated deficit by the same amount, and raised selling, general and administrative expense for the quarter by about $4.4 million. Revenue for the quarter remained $79.5 million, but gross profit dropped to $8.2 million.
Despite this, Core Scientific reported net income of $576.3 million for the quarter, largely driven by a $621.5 million non‑cash gain from changes in the fair value of warrants and contingent value rights. Operating cash flow was a $45.0 million outflow, and cash, cash equivalents and restricted cash ended at $698.7 million.
The company concluded the errors were material and that earlier financial statements for several 2024 and 2025 periods should no longer be relied upon. Management identified a material weakness in internal control over financial reporting and deemed controls ineffective for the 2024 and 2025 year‑ends and interim 2025 non‑reliance periods, and outlines remediation plans in its controls discussion.
Two Seas Capital and affiliates report beneficial ownership of 20,697,679 Core Scientific common shares, representing about 6.7% of the company, including shares underlying warrants and options. They have entered into a cooperation agreement with Core Scientific that reshapes the board and sets ownership and voting commitments.
The agreement calls for appointing three independent directors, one by March 15, 2026, a second around the 2026 annual meeting but no later than September 15, 2026, and a third before the 2027 annual meeting, each in consultation with Two Seas Capital. One current director will not stand for re-election at the 2027 meeting, and current board chair Jordan Levy will not stand for re-election at the 2026 meeting.
The cooperation agreement includes standstill terms, limiting Two Seas Capital from increasing its beneficial ownership to 9.9% or more of outstanding shares and requiring it to vote its shares at the 2026 and 2027 annual meetings in line with board recommendations.
Two Seas Capital and affiliates report beneficial ownership of 20,697,679 Core Scientific common shares, representing about 6.7% of the company, including shares underlying warrants and options. They have entered into a cooperation agreement with Core Scientific that reshapes the board and sets ownership and voting commitments.
The agreement calls for appointing three independent directors, one by March 15, 2026, a second around the 2026 annual meeting but no later than September 15, 2026, and a third before the 2027 annual meeting, each in consultation with Two Seas Capital. One current director will not stand for re-election at the 2027 meeting, and current board chair Jordan Levy will not stand for re-election at the 2026 meeting.
The cooperation agreement includes standstill terms, limiting Two Seas Capital from increasing its beneficial ownership to 9.9% or more of outstanding shares and requiring it to vote its shares at the 2026 and 2027 annual meetings in line with board recommendations.
Core Scientific, Inc. entered into a cooperation agreement with Two Seas Capital LP that will reshape its board over the next two years. The company will appoint one new independent director by March 15, 2026, a second by no later than September 15, 2026, and a third before the 2027 annual meeting, each in consultation with Two Seas.
Until the 2027 annual meeting, the board size will be capped at nine directors and cannot be reduced in a way that forces any of the new directors to resign without Two Seas’ consent. One current director will not be nominated for re-election at the 2027 meeting. Two Seas agreed to a one-year standstill, voting commitments through the 2027 annual meeting, and mutual non-disparagement. Separately, Chairman Jordan Levy told the board he will not stand for re-election at the 2026 annual meeting, citing personal reasons and no disagreement with the company.
Core Scientific, Inc. entered into a cooperation agreement with Two Seas Capital LP that will reshape its board over the next two years. The company will appoint one new independent director by March 15, 2026, a second by no later than September 15, 2026, and a third before the 2027 annual meeting, each in consultation with Two Seas.
Until the 2027 annual meeting, the board size will be capped at nine directors and cannot be reduced in a way that forces any of the new directors to resign without Two Seas’ consent. One current director will not be nominated for re-election at the 2027 meeting. Two Seas agreed to a one-year standstill, voting commitments through the 2027 annual meeting, and mutual non-disparagement. Separately, Chairman Jordan Levy told the board he will not stand for re-election at the 2026 annual meeting, citing personal reasons and no disagreement with the company.
Core Scientific, Inc. entered into a cooperation agreement with Two Seas Capital LP that will reshape its board over the next two years. The company plans to appoint one independent director by March 15, 2026, a second by no later than September 15, 2026, and a third before the 2027 annual meeting, all in consultation with Two Seas.
Until the 2027 annual meeting, the board size will be capped at nine directors and cannot be reduced in a way that forces any of the new directors to resign without Two Seas’ consent. One current director will not be nominated in 2027, and Chairman Jordan Levy has informed the company he will not stand for re-election at the 2026 annual meeting, a decision stated as not due to any disagreement. Two Seas agreed to a one-year standstill, longer voting commitments through the 2027 annual meeting, and mutual non-disparagement.
Core Scientific, Inc. entered into a cooperation agreement with Two Seas Capital LP that will reshape its board over the next two years. The company plans to appoint one independent director by March 15, 2026, a second by no later than September 15, 2026, and a third before the 2027 annual meeting, all in consultation with Two Seas.
Until the 2027 annual meeting, the board size will be capped at nine directors and cannot be reduced in a way that forces any of the new directors to resign without Two Seas’ consent. One current director will not be nominated in 2027, and Chairman Jordan Levy has informed the company he will not stand for re-election at the 2026 annual meeting, a decision stated as not due to any disagreement. Two Seas agreed to a one-year standstill, longer voting commitments through the 2027 annual meeting, and mutual non-disparagement.
Core Scientific, Inc. received a Schedule 13G showing that four affiliated Susquehanna entities together report beneficial ownership of 17,376,097 shares of common stock, or 5.6% of the company, as of the event date 12/31/2025.
The percentage is based on 310,061,300 shares outstanding as of October 20, 2025, as disclosed in the company’s Form 10-Q. Holdings include common stock, options and warrants across G1 Execution Services, SIG Brokerage, Susquehanna Investment Group and Susquehanna Securities.
Each firm has sole voting and dispositive power over its own positions and shared power over all reported shares. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Core Scientific, Inc. received a Schedule 13G showing that four affiliated Susquehanna entities together report beneficial ownership of 17,376,097 shares of common stock, or 5.6% of the company, as of the event date 12/31/2025.
The percentage is based on 310,061,300 shares outstanding as of October 20, 2025, as disclosed in the company’s Form 10-Q. Holdings include common stock, options and warrants across G1 Execution Services, SIG Brokerage, Susquehanna Investment Group and Susquehanna Securities.
Each firm has sole voting and dispositive power over its own positions and shared power over all reported shares. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Barclays PLC has disclosed a small ownership stake in Core Scientific Inc. The filing reports that Barclays beneficially owns 1,302,387 shares of Core Scientific common stock, representing 0.42% of the outstanding class.
Barclays reports 1,298,420 shares with sole voting and dispositive power and 3,967 shares with shared voting and dispositive power. The shares are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Barclays PLC has disclosed a small ownership stake in Core Scientific Inc. The filing reports that Barclays beneficially owns 1,302,387 shares of Core Scientific common stock, representing 0.42% of the outstanding class.
Barclays reports 1,298,420 shares with sole voting and dispositive power and 3,967 shares with shared voting and dispositive power. The shares are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.
The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.
Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.
The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.
Two Seas Capital and related reporting persons filed an amended ownership report for Core Scientific, Inc., disclosing beneficial ownership of 22,472,467 shares of common stock, or about 7.2% of the company. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 5,077,600 shares at an exercise price of $17 that expire on February 20, 2026. The position is held through various funds and accounts that have delegated sole voting and investment power to Two Seas Capital.
The filing states the securities were acquired for investment purposes in the ordinary course of business because they were viewed as an attractive opportunity. The reporting persons may engage with Core Scientific’s management, board, other shareholders, and market participants on topics such as business strategy, capital allocation, governance, and environmental and social matters. They also indicate they may increase or decrease their position or use derivatives and hedging strategies to adjust their economic exposure over time.
Two Seas Capital and related reporting persons filed an amended ownership report for Core Scientific, Inc., disclosing beneficial ownership of 22,472,467 shares of common stock, or about 7.2% of the company. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 5,077,600 shares at an exercise price of $17 that expire on February 20, 2026. The position is held through various funds and accounts that have delegated sole voting and investment power to Two Seas Capital.
The filing states the securities were acquired for investment purposes in the ordinary course of business because they were viewed as an attractive opportunity. The reporting persons may engage with Core Scientific’s management, board, other shareholders, and market participants on topics such as business strategy, capital allocation, governance, and environmental and social matters. They also indicate they may increase or decrease their position or use derivatives and hedging strategies to adjust their economic exposure over time.